Veru (VERU) Net Equity Issued and Repurchased (2018 - 2025)
Veru (VERU) posted quarterly Net Equity Issued and Repurchased of $23.4 million for Q4 2025, down 30.39% quarter-over-quarter from $33.6 million in Q2 2024.
Veru (VERU) Net Equity Issued and Repurchased (2018 - 2025) Analysis & Trends
Veru (VERU) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $23.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (down 30.39% YoY), while the FY2024 annual figure was $35.2 million, up 608.96% from the prior year.
- Net Equity Issued and Repurchased retreated to $23.4 million in Q4 2025 per VERU's latest filing, from $33.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $33.6 million in Q2 2024 and bottomed at -$8.4 million in Q2 2021.
- Historically, Net Equity Issued and Repurchased has averaged $8.2 million across 4 years, with a median of $5.0 million in 2023.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased slumped 268.0% — and 2024, when it surged 1405.32%.
- Veru's Net Equity Issued and Repurchased stood at -$8.4 million in 2021, then soared by 119.78% to $1.7 million in 2023, then jumped by 1920.3% to $33.6 million in 2024, then sank by 30.39% to $23.4 million in 2025.
- Business Quant data shows VERU's Net Equity Issued and Repurchased at $23.4 million in Q4 2025, $33.6 million in Q2 2024, and $1.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.37 Mn |
| Dec 31, 2025 | 23.37 Mn |
| Jun 30, 2024 | 33.57 Mn |
| Jun 30, 2024 | 33.57 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Jun 30, 2021 | -8.40 Mn |
| Jun 30, 2021 | -8.40 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Jun 30, 2020 | 5.00 Mn |
| Jun 30, 2020 | 5.00 Mn |
| Jun 30, 2019 | 3.60 Mn |
| Jun 30, 2019 | 3.60 Mn |
| Mar 31, 2019 | 9.13 Mn |
| Mar 31, 2019 | 9.13 Mn |